AVLN Stock — Avalyn Pharma Inc.

Avalyn Pharma Inc. (AVLN)

Updated October 16, 2026.

AVLN is a Stock. Total return is -19.8% over the past 0.5 years, 26.5 points behind SPY at 6.7%.

Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, particularly pulmonary fibrosis and other interstitial lung diseases, with a pipeline focused on inhaled formulations of existing oral medicines delivered directly to the lungs. The company does not currently have an established distribution schedule. This security appeals to investors seeking exposure to early-stage pharmaceutical development with potential in rare respiratory disease treatments.

AVLN performance versus SPY

Price and return data through 2026-10-16.

Total return is -19.8% over the past 0.5 years, 26.5 points behind SPY at 6.7%.

AVLN key facts

Asset type

Stock

Asset class

Equity

Inception date

04/30/2026

Distribution frequency

None

Last close

$23.66 (as of 2026-10-16)

Market cap

$1,048,921,028

Average volume

291431.0

Payout ratio

0.0%

EPS

$-2.47

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

AVLN risks and drawbacks

Total return has trailed SPY over the available window.

Who may consider AVLN — and who may not

It is a weaker fit for investors who need monthly cash flow (AVLN does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on AVLN

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions